Welcome to our dedicated page for MetaVia SEC filings (Ticker: MTVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MetaVia Inc. (MTVA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biotechnology issuer focused on cardiometabolic diseases. MetaVia files reports with the U.S. Securities and Exchange Commission under Commission File Number 001-37809 as a Delaware corporation with principal offices in Cambridge, Massachusetts. These filings offer detailed information on clinical progress, financial results, capital market actions, and interactions with The Nasdaq Capital Market.
Among MetaVia’s recent filings are several Current Reports on Form 8-K that describe material events. One 8-K discusses a notice from Nasdaq regarding non-compliance with the minimum bid price requirement and a subsequent 180-day extension to May 26, 2026 to regain compliance, as well as the company’s intention to consider options such as a reverse stock split. Another 8-K references the company’s press release announcing a 1-for-11 reverse stock split of its common stock, which was implemented to help meet Nasdaq’s continued listing standards. A later press release, also furnished via 8-K, reports that MetaVia regained compliance with Nasdaq’s minimum bid price requirement and that the listing matter was closed.
Other 8-K filings furnish clinical and corporate updates, including positive Phase 2a data for vanoglipel (DA-1241) in presumed MASH patients and references to improvements in HbA1c, liver inflammation, fibrosis markers, and lipidomic profiles. MetaVia also uses Form 8-K to furnish its quarterly financial results and to provide access to updated corporate presentations, which summarize the status of its DA-1726 and vanoglipel programs and outline its cardiometabolic disease strategy.
Through Stock Titan, users can review these MetaVia SEC filings in one place and use AI-powered tools to summarize key points from complex disclosures. Filings such as 10-K annual reports, 10-Q quarterly reports, and additional 8-K current reports, when available, can help investors and analysts understand MetaVia’s R&D spending, clinical development milestones, capital structure changes, and Nasdaq listing compliance history. Insider transaction reports on Form 4, if filed, can also be accessed to see reported purchases or sales by MetaVia’s officers, directors, or significant shareholders.
MetaVia Inc. filed an 8-K stating it posted an updated corporate presentation on its investor website and furnished it as Exhibit 99.1. The presentation may be used in investor communications and conferences.
The company noted the materials contain forward-looking statements and are subject to the cautionary statements in the exhibit and in its SEC reports.
MetaVia Inc. (MTVA) reported Q3 2025 results showing a narrower net loss and lower spending while advancing its cardiometabolic pipeline. Net loss was $3.38 million on total operating expenses of $3.48 million, driven by a sharp reduction in R&D. Cash ended the quarter at $14.28 million with warrant liabilities of $0.17 million and stockholders’ equity of $6.33 million.
The company disclosed that conditions raise substantial doubt about its ability to continue as a going concern, despite stating existing cash should fund operations into 2026. MetaVia strengthened liquidity with a May 2025 private placement (net proceeds $9.1 million) and, on November 6, entered an at‑the‑market program of up to $2.3 million (3% commission) under its S‑3 shelf. Development highlights include positive Phase 2a top‑line for Vanoglipel (DA‑1241) and ongoing DA‑1726 Phase 1 multidose work, with 48 mg cohort top‑line expected in Q4 2025. As of November 5, 2025, common shares outstanding were 24,214,788.
MetaVia Inc. (MTVA) furnished an Item 2.02 Form 8-K announcing financial results for the third quarter ended September 30, 2025 and providing a corporate update. The details are contained in a press release furnished as Exhibit 99.1.
The information is furnished and not deemed "filed" under Section 18 of the Exchange Act. The company included forward-looking statements cautions. The report was signed by President and CEO Hyung Heon Kim. MetaVia’s common stock trades on Nasdaq under ticker MTVA.